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chotics. During the ﬁrst 150 days from the initiation 
of therapy, rivastigmine patients were 81% (RR = 0.19;
95% CI: 0.05–0.63) less likely to use antipsychotic drugs
compared to non-ChEI users. CONCLUSIONS: AD
patients who take rivastigmine are less likely to take
antipsychotics compared to those not taking ChEIs. These
ﬁndings imply that rivastigmine use may delay the 
progression of the development of behavioral symptoms
of AD.
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OBJECTIVES: This study explores the use of the WHO’s
ICIDH-2 in determining domains of mental functioning
impairment in migraineurs. METHODS: Seventy-one
migraine functioning questions were generated from
focus groups in the US and Germany and classiﬁed using
the ICIDH-2 system. A Phase I questionnaire imple-
mented in the US and Germany was used to identify items
of greatest relevance to migraineurs. Principal compo-
nents analysis (PCA) with Varimax rotation was used to
identify factors from relevant items in Phase I data. These
items were tested in a Phase II study in the US and
Germany and conﬁrmatory factor analysis (CFA) was
conducted to determine if the factor structure found in
Phase I remained intact. Statistics to assess ﬁt of the CFA
model included the chi-squared test which is insigniﬁcant
in good ﬁtting models, the RMSEA in which values less
than 0.05 indicate good ﬁt, and the NNFI which should
be at least 0.95 to indicate a strong model. RESULTS:
The Phase I PCA conducted in the US sample identi-
ﬁed four factors consistent with the ICIDH-2:
“Energy/Sleep”, “Perception”, “Attention/Thought”, and
“Emotion”. In Germany, the same factors were identiﬁed
with the exception of “Energy/Sleep”. Emotion items
were not included in Phase II in order to focus on func-
tioning alone. CFA of the Phase II data found that a
model including “Attention/Thought”, “Perception”, and
“Energy/Sleep” did not ﬁt well. After additional item
reduction, however, a model with “Perception” and
“Attention/Thought” showed excellent performance in
CFA with a chi-squared value of 33.04 (d.f. = 26, p =
0.16), RMSEA of 0.042 (90%CI 0.00–0.08) and NNFI
of 0.99. CONCLUSIONS: The ICIDH-2 mental func-
tioning dimensions with the greatest impact on
Migraineurs are Perception and Attention/Thought. Emo-
tional function was also an important factor. This
research supports the hypothesis that the ICIDH-2 can be
used in classifying areas of impairment for outcomes
assessment.
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OBJECTIVES: Attention deﬁcit hyperactivity disorder
(ADHD) is a prevalent mental health condition, occur-
ring in 3–5% of children. Although stimulant medications
are a recommended treatment for this disorder, physi-
cians’ views of these medications have not been system-
atically evaluated. This study examined physician
perceptions of using medications to treat ADHD symp-
toms in children and/or adolescents. METHODS: A
survey was developed with four physician experts in treat-
ing ADHD in children. The survey was pilot tested with
a sample of 10 practicing physicians. A sample of 1000
physicians, with a history of prescribing stimulant med-
ications to children and/or adolescents, was randomly
selected and mailed a 30-item survey. Items were rated on
a 7-point response scale (strongly agree, agree, slightly
agree, undecided, slightly disagree, disagree, strongly dis-
agree). RESULTS: A total of 365 physicians responded to
the survey, for a 36.5% response rate. Over 98% physi-
cians agreed that ADHD symptoms cause problems in
pediatric patients and that stimulants are effective in
treating ADHD. The stimulant side effects 
of decreased appetite/weight loss, sleep disruption, and
exacerbation of anxiety were a concern to 88%, 74%,
and 63% of physicians, respectively. Physicians reported
that controlled medications for children and/or adoles-
cents with ADHD are a burden for themselves (55%
agreed), for their staff (61% agreed), and for parents
(66% agreed). Diversion of ADHD medication was a
concern to 53% of respondents. Approximately 55% of
physicians responded that they would prefer prescribing
a non-stimulant medication with a FDA-indication for
treating children and/or adolescents instead of a stimu-
lant medication. CONCLUSIONS: Although physicians
overwhelmingly perceive stimulant medications as being
effective for treating ADHD symptoms in children and/or
adolescents, the majority would prefer a non-stimulant
medication. Their concerns related to side effects, diver-
sion, and burden of prescribing associated with stimu-
lants may be reasons for their preference.
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OBJECTIVES: Traditional database methodology suggest
patient selection be done through ICD codes when inter-
